Skip to main content

Advertisement

SpringerLink
Log in

Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

The association of pathology and neurological deficit with quality of life (QoL) in multiple sclerosis (MS) is not fully understood. In this study, magnetic resonance imaging (MRI) measures of pathology—T1 and T2 lesion volume and ratio; active T2 lesion number; global and regional brain volume and atrophy; magnetization transfer ratio (MTR) for lesions, normal appearing grey and white matter (NAGM, NAWM); and spinal cord cross-sectional area—and measures of neurological disability (expanded disability status scale, EDSS), deficit (MS functional composite, MSFC) and inflammatory activity (relapse rate) were compared with the MS impact scale (MSIS-29), in participants in a trial of lamotrigine in secondary progressive MS. Data were collected from 118 people (85 female:33 male) aged 30–61 years (mean 50.6 years)—median EDSS 6.0 (range 4.0–7.5); mean disease duration 20.1 years (range 3–41)—at baseline and 2 years. Regression analysis was used to identify independently significant cross-sectional and longitudinal correlates of the physical (MSIS-phys) and psychological (MSIS-psych) components of the MSIS-29; longitudinal analysis using the 57 people in the placebo arm. The only independently significant correlate of MSIS-phys was 1/timed walk (TW) (p < 0.0001, R 2 = 0.13; p = 0.047, R 2 = 0.09); cross-sectionally the best model for MSIS-psych was the paced auditory serial addition test (PASAT-3) (p = 0.041) and T1-to-T2 lesion volume ratio (p = 0.009) (R 2 = 0.13); longitudinally it was change in 1/TW (p = 0.007), mean NAWM MTR (p = 0.003) and NAGM peak height (p = 0.048) (R 2 = 0.32). These data show that MRI measures and clinical measures do impact on quality of life, but the association is limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Confavreux C, Vukusic S, Moreau T, Adelein P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438

    Article  PubMed  CAS  Google Scholar 

  2. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913

    Article  PubMed  Google Scholar 

  3. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro A, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929

    Article  PubMed  Google Scholar 

  4. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in lesions of multiple sclerosis. N Engl J Med 338:278–285

    Article  PubMed  CAS  Google Scholar 

  5. Kutzelnigg A, Luchinetti CF, Stadelman C, Bruck W, Rauschka H, Bermann M, Schmidbauer M, Parisi JE, Lassman H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712

    Article  PubMed  Google Scholar 

  6. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676–1695

    Article  PubMed  Google Scholar 

  7. Li DKB, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M, and for the Sylvia Lawry Centre for MS Research MRI (2006) T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66:1384–1389

    Article  PubMed  CAS  Google Scholar 

  8. Filippi M, Agosta F. (2007) Magnetization transfer MRI in multiple sclerosis. J Neuroimaging. Suppl 1:22S-26S

    Google Scholar 

  9. Rothwell PM, McDowell D, Wong CK, Dornan PJ (1997) Doctors and patients don’t agree: cross-sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 314:1580–1583

    Article  PubMed  CAS  Google Scholar 

  10. Newcombe J, Hawkins CP, Henderson CL, Patel HA, Woodroofe MN, Hayes GM, Cuzner ML, MacManus D, du Boulay EP, McDonald WI (1991) Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 114:1013–1023

    Article  PubMed  Google Scholar 

  11. Naismith RT, Cross AH (2005) Multiple sclerosis and black holes: connecting the pixels. Arch Neurol 62:1666–1668

    Article  PubMed  Google Scholar 

  12. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    PubMed  CAS  Google Scholar 

  13. Fischer JS, Rudick RA, Cutter GR, Reingold SC, The national MS society clinical outcomes assessment task force (1999) The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 5:244–250

    PubMed  CAS  Google Scholar 

  14. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001) The multiple sclerosis impact scale: a new patient-based outcome measure. Brain 124:962–973

    Article  PubMed  CAS  Google Scholar 

  15. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ (2002) Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatr 73:701–704

    Article  PubMed  CAS  Google Scholar 

  16. Hoogervorst ELJ, Zwemmer JNP, Jelles B, Polman CH, Uitdehaag BMJ (2004) Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler 10:569–574

    Article  PubMed  CAS  Google Scholar 

  17. Costelloe L, O’Rourke K, McGuigan C, Walsh C, Tubridy N, Hutchinson M (2008) The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite. Mult Scler 14:255–258

    Article  PubMed  CAS  Google Scholar 

  18. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH (2010) A randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Lancet Neurol 9:681–688

    Article  PubMed  CAS  Google Scholar 

  19. Cutter GR, Baier MS, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Synulko K, Weinshenker BG, Antel JP, Confavreaux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882

    Article  PubMed  Google Scholar 

  20. Plummer DL (1992) Dispimage: a display and analysis tool for medical images. Revsita Di Neuroradiologica 5:489–495

    Google Scholar 

  21. Molyneux PD, Miller DH, Filippi M, Yousry TA, Radii EV, Ader HJ, Barkhof F (1999) Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. Neuroradiology 41:882–888

    Article  PubMed  CAS  Google Scholar 

  22. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17:479–489

    Article  PubMed  Google Scholar 

  23. Losseff NA, Webb SL, O’Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ (1996) Spinal cord atrophjy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701–708

    Article  PubMed  Google Scholar 

  24. Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257:1508–1516

    Article  PubMed  CAS  Google Scholar 

  25. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi (2000) The effect of interferon Beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on interferon beta-b in secondary progressive multiple sclerosis. Brain 123:2256–2263

    Article  PubMed  Google Scholar 

  26. CAMMS223 Trial Investigators (2008) Alemtuzumab vs interferon beta -1a in earlt multiple sclerosis. N Eng J Med 359:1786–1801

    Article  Google Scholar 

  27. Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RAC, Hunter K, Tozer D, Miller DH, Kapoor R (2009) Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 256:427–435

    Article  PubMed  CAS  Google Scholar 

  28. Ash burner J, Friston KJ (2005) Unified segmentation. Neuroimage 26:839–851

    Article  Google Scholar 

  29. Losseff NA, Wang L, Lau HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009–2019

    Article  PubMed  Google Scholar 

  30. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH (2008) Disability as an outcome in MS clinical trials. Neurology 7:624–631

    Article  Google Scholar 

  31. Benito-Leon JN, Morales JM, Rivera-Navarro JS, Mitchell AJ (2003) A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 25:1291–1303

    Article  PubMed  Google Scholar 

  32. Janhardan V, Bakshi R (2000) Quality of life and its relationship to brain lesions and atrophy on magnetice resonance images in 60 patients with multiple sclerosis. Arch Neurol 57:1485–1490

    Article  Google Scholar 

  33. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H, Kristoferitsch W, Zeitlhofer J (2004) Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 110:6–13

    Article  PubMed  CAS  Google Scholar 

  34. Isaksson A-K, Ahlstrom G, Gunnarsson L-G (2005) Quality of life in patients with multiple sclerosis. J Neurol Neurosurg Psychiatr 76:64–69

    Article  PubMed  Google Scholar 

  35. Simeoni MC, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constaninescu C, Idiman E, Boyko A, Beiske AG, Vollmer T, Triantafylliou N, O’Connor P, Barak Y, Beirmann L, Cristiano E, Atweh S, Patrick DL, Robitail S, Ammoury N, Beresniak A, Pelletier J, on behalf of the MusiQol study group (2008) Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler 14:219–230

    Article  PubMed  Google Scholar 

  36. Nordvedt MW, Riise T, Myhr K-M, Nyland HI (2000) Performance of the SF-36, SF-12 and Rand-36 summary scales in a multiple sclerosis population. Med Care 10:1022–1028

    Article  Google Scholar 

  37. Gold SM, Heeson C, Schultz H, Guder U, Monch A, Gbadamosi J, Buhmann C, Schultz KH (2001) Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in multiple sclerosis (HAQUAMS). Mult Scler 7:119–130

    PubMed  CAS  Google Scholar 

  38. Benito-Leon J, Morales JM, Riviera-Navarro J (2002) European journal of neurology health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 9:497–502

    Article  PubMed  CAS  Google Scholar 

  39. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 231:29–34

    Article  PubMed  Google Scholar 

  40. Mitchell AJ, Benito-León J, Morales González J-M, Rivera-Navarro J (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 4:556–566

    Article  PubMed  Google Scholar 

  41. Ytterberg C, Johansson S, Holmqvist LW, von Koch L (2008) Longitudinal variations and predictors of increased perceived impact of multiple sclerosis, a two-year study. J Neurol Sci 270:53–59

    Article  PubMed  Google Scholar 

  42. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D (2009) Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 72:1760–1765

    Article  PubMed  CAS  Google Scholar 

  43. van Walderveen MAA, Kamphorst W, Scheltens P, van Waesberghe JHTM, Ravid R, Valk J, Polman CH, Barkhof F (1998) Histopathologic correlate of hypointense spin-echo lesions on Tl-weighted MRI in multiple sclerosis. Neurology 50:1282–1288

    PubMed  Google Scholar 

  44. van Waesberghe JHTM, Kamphorst W, De Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754

    Article  PubMed  Google Scholar 

  45. Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, Rudick RA, Trapp BD (2007) Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 62:219–228

    Article  PubMed  Google Scholar 

  46. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153–1158

    Article  PubMed  CAS  Google Scholar 

  47. Codella M, Rocca MA, Colombo B, Rossi P, Comi G, Filippi M (2002) A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. J Neurol 249:535–537

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the radiographers in the NMR Research Unit at the Institute of Neurology, London and all the subjects who participated in the study. The authors would also like to thank Dr M Cercignani, Dr D Chard, Dr G Davies, Dr KTM Fernando, Dr L Fisniku, Prof RAC Hughes, Dr Z Khaleeli, Dr A Shenoy, Dr D Soon, Dr J Swanton and Dr A Traboulsee for their advice. This work was funded by the MS society of Great Britain and Northern Ireland and was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme.

Conflict of interest

RK has received honoraria from Biogen Idec, Merck Serono and MS Therapeutics for participation in scientific advisory boards, and travel or accommodation expenses have been covered by Biogen Idec, Merck Serono, and Teva. KJS has received consultancy fees from Merck Serono, and has received support from the Brain Research Trust for preclinical work on sodium-channel blockade in inflammatory neuropathy. RB has received honoraria from Merck Serono for participation in advisory boards, and travel or accommodation expenses have been covered by Biogen Idec and Merck Serono. JC has received consultancy fees from Biogen Idec. For DHM, University College London Institute of Neurology has received payments for membership of multiple sclerosis trial advisory boards of Biogen Idec, Bayer Schering, GlaxoSmithKline, and Novartis; payments for consultancies with Biogen Idec, GlaxoSmithKline, and Novartis; honoraria from Biogen Idec, GlaxoSmithKline, Novartis, the National Institutes of Health, and the University of Texas Health Science Center; payments for travel or accommodation from Biogen Idec, the Consortium of MS Societies, and GlaxoSmithKline; and research grants from the MS Society (UK), Biogen Idec, Novartis, GlaxoSmithKline, Genzyme, and the National Institute for Health Research. JF, TH, KH, DJT and DRA have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK

    T. Hayton, J. Furby, K. J. Smith, K. Hunter, D. J. Tozer, D. H. Miller & R. Kapoor

  2. London School of Hygiene and Tropical Medicine, London, UK

    D. R. Altmann

  3. Department of Neurology, Royal Free Hospital, London, UK

    R. Brenner

  4. National Hospital for Neurology and Neurosurgery, London, UK

    J. Chataway

Authors
  1. T. Hayton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Furby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. J. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. R. Altmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Chataway
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. J. Tozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. H. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Hayton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayton, T., Furby, J., Smith, K.J. et al. Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol 259, 237–245 (2012). https://doi.org/10.1007/s00415-011-6151-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-6151-5

Keywords

Search

Navigation